Subscribe To
Zynerba pharmaceuticals names new clo & corporate secretary
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, <...
February 15, 2022, 8:14 am
Zynerba pharmaceuticals names new clo & corporate secretary
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, <...
February 15, 2022, 8:14 am
Should you invest in the invesco dynamic biotechnology & genome etf (pbe)?
Sector ETF report for PBE...
February 15, 2022, 7:44 am
Should you invest in the invesco dynamic biotechnology & genome etf (pbe)?
Sector ETF report for PBE...
February 15, 2022, 7:44 am
Should you invest in the invesco dynamic biotechnology & genome etf (pbe)?
Sector ETF report for PBE...
February 15, 2022, 7:44 am
Xbi and ibb: sell technology and buy biotech, the only undervalued non-cyclical growth sector
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the te...
February 15, 2022, 3:11 am
Xbi and ibb: sell technology and buy biotech, the only undervalued non-cyclical growth sector
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the te...
February 15, 2022, 3:11 am
Xbi and ibb: sell technology and buy biotech, the only undervalued non-cyclical growth sector
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the te...
February 15, 2022, 3:11 am
Longeveron: speculative biotech worth a look on rare disease, aging, and alzheimer's focuses
Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B ...
February 14, 2022, 10:01 pm
Longeveron: speculative biotech worth a look on rare disease, aging, and alzheimer's focuses
Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B ...
February 14, 2022, 10:01 pm
Longeveron: speculative biotech worth a look on rare disease, aging, and alzheimer's focuses
Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B ...
February 14, 2022, 10:01 pm
Some old school stocks help futuristic healthcare etf
When many investors think of healthcare innovation, they focus on companies in industries such as biotechnology, medical devices, telehealth and more....
February 14, 2022, 4:57 pm
Some old school stocks help futuristic healthcare etf
When many investors think of healthcare innovation, they focus on companies in industries such as biotechnology, medical devices, telehealth and more....
February 14, 2022, 4:57 pm
Some old school stocks help futuristic healthcare etf
When many investors think of healthcare innovation, they focus on companies in industries such as biotechnology, medical devices, telehealth and more....
February 14, 2022, 4:57 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful con...
February 14, 2022, 2:10 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful con...
February 14, 2022, 2:10 pm
Moleculin biotech annamycin doublet therapy shows 68% overall survival in animal study
Moleculin biotech Inc (NASDAQ: MBRX) has announced preliminary results supporting the successful con...
February 14, 2022, 2:10 pm
Q biomed outlines strategic direction and goals for 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the ...
February 14, 2022, 1:21 pm
Q biomed outlines strategic direction and goals for 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the ...
February 14, 2022, 1:21 pm
Q biomed outlines strategic direction and goals for 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the ...
February 14, 2022, 1:21 pm